News Sentiment

PLYX sentiment intelligence

Polaryx Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.28 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-2.1% over one week, -1.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Polaryx Therapeutics Announces Chief Medical Officer Resignation

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -2.1% Price reacting lower
Trend fit Trend inactive -1.7% over four weeks
Fair value -44.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 34
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 9
Stock Titan 4
MarketBeat 4
simplywall.st 3
Bitget 2
Moomoo 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 18
Balance sheet 6
Analyst action 5
Regulatory and legal 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Investing.com Direct company coverage

Polaryx Therapeutics CEO’s Mstone buys $360,003 in PLYX stock

Mstone Partners Healthcare Ltd, an entity where Polaryx Therapeutics CEO Alex Keun Mo Yang serves as founder and CEO, purchased 88,453 shares of Polaryx Therapeutics (PLYX) common stock for $360,003 in a private placement. This transaction occurred on May 27, 2026, at $4.07 per s

Tone
Positive 70/100
Event
Market update
Published
29 May 2026 00:09
Source
Investing.com
Stock Titan Direct company coverage

Polaryx (PLYX) secures $10M PIPE to fund SOTERIA trial and extend runway to Q2 2027

Polaryx Therapeutics, Inc. (PLYX) has announced a $10 million private placement, selling 2,502,696 common shares at a weighted average price of $4.00 per share. These proceeds, combined with existing cash, will fund the initiation of the Phase 2 SOTERIA basket trial for PLX-200 a

Tone
Positive 71/100
Event
Balance sheet
Published
28 May 2026 20:08
Source
Stock Titan
Stock Titan Direct company coverage

Polaryx raises $10M to launch 2026 PLX-200 trial in rare pediatric lysosomal diseases

Polaryx Therapeutics has successfully closed a $10 million private investment in public equity (PIPE) financing, issuing 2,502,696 common shares at approximately $4.00 each. These funds are designated to initiate the Phase 2 SOTERIA basket trial of PLX-200, targeting multiple lys

Tone
Positive 72/100
Event
Market update
Published
28 May 2026 12:39
Source
Stock Titan
Finviz Direct company coverage

PLYX - Polaryx Therapeutics Inc Stock Price and Quote

Polaryx Therapeutics Inc (PLYX) stock experienced a significant ~28% drop, driven by concerns over cash runway and going concern doubts. The company recently received multiple FDA Fast Track Designations for its SOTERIA basket trial and is actively participating in healthcare con

Tone
Negative 19/100
Event
Balance sheet
Published
26 May 2026 20:09
Source
Finviz
Minichart Direct company coverage

Polaryx Therapeutics, Inc. Q1 2026 Financial Results and Pipeline Update: Progress in Rare Pediatric Lysosomal Storage Disorder Therapies

Polaryx Therapeutics, Inc. reported a Q1 2026 net loss of $2.5 million and an accumulated deficit of $102.2 million, with only $250,000 in cash. The company faces significant financial risks, including a "going concern" warning due to recurring losses and limited cash, necessitat

Tone
Neutral 50/100
Event
Balance sheet
Published
15 May 2026 21:40
Source
Minichart